JP2016524611A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016524611A5 JP2016524611A5 JP2016515080A JP2016515080A JP2016524611A5 JP 2016524611 A5 JP2016524611 A5 JP 2016524611A5 JP 2016515080 A JP2016515080 A JP 2016515080A JP 2016515080 A JP2016515080 A JP 2016515080A JP 2016524611 A5 JP2016524611 A5 JP 2016524611A5
- Authority
- JP
- Japan
- Prior art keywords
- level
- cancer
- vegf
- fgf2
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361826975P | 2013-05-23 | 2013-05-23 | |
| US61/826,975 | 2013-05-23 | ||
| US201461936471P | 2014-02-06 | 2014-02-06 | |
| US61/936,471 | 2014-02-06 | ||
| US201461974279P | 2014-04-02 | 2014-04-02 | |
| US61/974,279 | 2014-04-02 | ||
| PCT/US2014/039129 WO2014190147A2 (en) | 2013-05-23 | 2014-05-22 | Methods of treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018169261A Division JP2019023193A (ja) | 2013-05-23 | 2018-09-11 | がんを治療する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016524611A JP2016524611A (ja) | 2016-08-18 |
| JP2016524611A5 true JP2016524611A5 (enExample) | 2017-07-13 |
Family
ID=51934346
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016515080A Pending JP2016524611A (ja) | 2013-05-23 | 2014-05-22 | がんを治療する方法 |
| JP2018169261A Pending JP2019023193A (ja) | 2013-05-23 | 2018-09-11 | がんを治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018169261A Pending JP2019023193A (ja) | 2013-05-23 | 2018-09-11 | がんを治療する方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9775881B2 (enExample) |
| EP (2) | EP3252171B8 (enExample) |
| JP (2) | JP2016524611A (enExample) |
| KR (1) | KR20160013092A (enExample) |
| CN (1) | CN105307669A (enExample) |
| AU (1) | AU2014268519A1 (enExample) |
| BR (1) | BR112015029145A2 (enExample) |
| CA (1) | CA2909689A1 (enExample) |
| HK (1) | HK1219513A1 (enExample) |
| MX (1) | MX2015015426A (enExample) |
| RU (1) | RU2015154985A (enExample) |
| SG (2) | SG11201509596YA (enExample) |
| WO (1) | WO2014190147A2 (enExample) |
| ZA (1) | ZA201507762B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201509596YA (en) * | 2013-05-23 | 2015-12-30 | Five Prime Therapeutics Inc | Methods of treating cancer |
| WO2016090546A1 (en) * | 2014-12-09 | 2016-06-16 | Wentao Zhang | Nbp158 and uses thereof |
| GB201609402D0 (en) * | 2016-05-27 | 2016-07-13 | Cancer Res Inst Royal | Materials and methods for treating cancer |
| JP2021518532A (ja) * | 2018-03-16 | 2021-08-02 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | がんにおける治療薬に対する応答の分析 |
| US20250304694A1 (en) * | 2022-06-29 | 2025-10-02 | Korea University Research And Business Foundation | Glycosylated fc variants of which binding affinity for human fcgrs is removed |
| WO2025221718A1 (en) * | 2024-04-15 | 2025-10-23 | Arizona Board Of Regents On Behalf Of Arizona State University | Repurposing fda approved therapeutics |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| GEP20033082B (en) | 1991-03-15 | 2003-10-27 | Amgen Inc | Pegylation of Polypeptides |
| US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| US20030206899A1 (en) | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| DK1975181T3 (da) | 1992-10-28 | 2011-06-06 | Genentech Inc | Anvendelse af vaskulære endothelcelle-vækstfaktor-antagonister |
| US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| IL132240A0 (en) | 1997-04-07 | 2001-03-19 | Genentech Inc | Anti-vegf antibodies |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| DE69832970T2 (de) | 1997-04-07 | 2006-08-10 | Genentech, Inc., South San Francisco | Humanisierte antikörper und verfahren zu ihrer herstellung |
| AU6366999A (en) | 1998-10-30 | 2000-05-22 | Takeda Chemical Industries Ltd. | Betacellulin protein-containing preparations |
| US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| US20020081597A1 (en) | 2000-03-31 | 2002-06-27 | Genentech, Inc. | Compositions and methods for detecting and quantifying gene expression |
| US6900292B2 (en) | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
| JP4810427B2 (ja) | 2003-05-22 | 2011-11-09 | アボット・ラボラトリーズ | インダゾール、ベンズイソオキサゾールおよびベンズイソチアゾールキナーゼ阻害剤 |
| NZ621449A (en) | 2003-05-30 | 2015-07-31 | Genentech Inc | Treatment with anti-vegf antibodies |
| WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| US20060009360A1 (en) | 2004-06-25 | 2006-01-12 | Robert Pifer | New adjuvant composition |
| WO2006076288A2 (en) | 2005-01-11 | 2006-07-20 | Five Prime Therapeutics, Inc. | Dna constructs for long-term expression of intravascularly injected naked dna |
| WO2006088767A2 (en) * | 2005-02-14 | 2006-08-24 | Florida State University Research Foundation, Inc. | C10 cyclopropyl ester substituted taxane compositions |
| ES2336832T3 (es) | 2005-07-22 | 2010-04-16 | Five Prime Therapeutics, Inc. | Composiciones y procedimientos para tratar enfermedades con proteinas de fusion de fgfr. |
| EP1942884A4 (en) * | 2005-11-04 | 2010-01-06 | Merck & Co Inc | METHOD FOR THE TREATMENT OF CANCER WITH SAHA, CARBOPLATIN AND PACLITAXEL AND OTHER COMBINATION THERAPIES |
| AR063975A1 (es) * | 2006-11-28 | 2009-03-04 | Centelion | Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada |
| CN101855553B (zh) | 2007-06-29 | 2014-06-11 | 韩国安国药品株式会社 | 卵巢癌的预测标记 |
| TWI580694B (zh) | 2007-11-30 | 2017-05-01 | 建南德克公司 | 抗-ｖｅｇｆ抗體 |
| US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| BR112013012041A2 (pt) * | 2010-11-15 | 2016-11-08 | Five Prime Therapeutics Inc | ''terapias de combinações de domínio extracelular fgfr1" |
| US8951972B2 (en) * | 2010-12-09 | 2015-02-10 | Five Prime Therapeutics, Inc. | FGFR1 extracellular domain combination therapies for lung cancer |
| CN102219860B (zh) * | 2011-05-20 | 2012-09-12 | 烟台荣昌生物工程有限公司 | FGFR-Fc融合蛋白及其用途 |
| MX2013014151A (es) * | 2011-06-03 | 2014-01-23 | Hoffmann La Roche | Metodos para tratar el mesotelioma con un compuesto inhibidor de la pi3k. |
| SG11201509596YA (en) * | 2013-05-23 | 2015-12-30 | Five Prime Therapeutics Inc | Methods of treating cancer |
-
2014
- 2014-05-22 SG SG11201509596YA patent/SG11201509596YA/en unknown
- 2014-05-22 KR KR1020157035893A patent/KR20160013092A/ko not_active Withdrawn
- 2014-05-22 MX MX2015015426A patent/MX2015015426A/es unknown
- 2014-05-22 EP EP17177845.9A patent/EP3252171B8/en active Active
- 2014-05-22 US US14/890,047 patent/US9775881B2/en active Active
- 2014-05-22 CN CN201480028853.4A patent/CN105307669A/zh active Pending
- 2014-05-22 AU AU2014268519A patent/AU2014268519A1/en not_active Abandoned
- 2014-05-22 JP JP2016515080A patent/JP2016524611A/ja active Pending
- 2014-05-22 HK HK16107529.7A patent/HK1219513A1/zh unknown
- 2014-05-22 CA CA2909689A patent/CA2909689A1/en not_active Abandoned
- 2014-05-22 EP EP14800459.1A patent/EP2999799A4/en not_active Withdrawn
- 2014-05-22 RU RU2015154985A patent/RU2015154985A/ru not_active Application Discontinuation
- 2014-05-22 BR BR112015029145A patent/BR112015029145A2/pt not_active IP Right Cessation
- 2014-05-22 SG SG10201703977UA patent/SG10201703977UA/en unknown
- 2014-05-22 WO PCT/US2014/039129 patent/WO2014190147A2/en not_active Ceased
-
2015
- 2015-10-16 ZA ZA2015/07762A patent/ZA201507762B/en unknown
-
2018
- 2018-09-11 JP JP2018169261A patent/JP2019023193A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kienast et al. | Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy | |
| Hidalgo et al. | First-in-human phase I study of single-agent vanucizumab, a first-in-class bispecific anti-angiopoietin-2/anti-VEGF-A antibody, in adult patients with advanced solid tumors | |
| Clarke et al. | Understanding and targeting resistance to anti-angiogenic therapies | |
| Lazăr et al. | New advances in targeted gastric cancer treatment | |
| Deng et al. | Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges | |
| Chan et al. | Targeted therapy for non-small cell lung cancer: current standards and the promise of the future | |
| Rougier et al. | Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer | |
| Cheng et al. | Molecularly targeted drugs for metastatic colorectal cancer | |
| Aprile et al. | Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use | |
| Li et al. | Current molecular targeted therapy in advanced gastric cancer: A comprehensive review of therapeutic mechanism, clinical trials, and practical application | |
| Rivera et al. | Cetuximab, its clinical use and future perspectives | |
| Jitawatanarat et al. | Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib | |
| Lee et al. | Options for second-line treatment in metastatic colorectal cancer | |
| Vergote et al. | A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma | |
| Balsano et al. | State of the art for metastatic pancreatic cancer treatment: Where are we now? | |
| Vermorken et al. | A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors | |
| Seystahl et al. | Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma? | |
| Lee et al. | Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors | |
| Oh et al. | Comprehensive review of the resistance mechanisms of colorectal cancer classified by therapy type | |
| Wang et al. | Advances in drugs targeting lymphangiogenesis for preventing tumor progression and metastasis | |
| Mok et al. | Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non‐squamous non‐small cell lung cancer who have not received prior chemotherapy: A substudy of the Avastin in Lung trial | |
| Li et al. | Combination of anti-EGFR and anti-VEGF drugs for the treatment of previously treated metastatic colorectal cancer: a case report and literature review | |
| Koukourakis et al. | Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer | |
| RU2015154985A (ru) | Способы лечения рака | |
| Pai et al. | Novel therapeutic agents in the treatment of metastatic colorectal cancer |